255 件 ・ 関連度順
概要と使いどころ
React composition patterns that scale. Use when refactoring components with boolean prop proliferation, building flexible component libraries, or designing reusable APIs. Triggers on tasks involving compound components, render props, context providers, or component architecture. Includes React 19 API changes.
日本語の概要は準備中です。原文の説明を表示しています。
React composition patterns that scale. Use when refactoring components with boolean prop proliferation, building flexible component libraries, or designing reusable APIs. Triggers on tasks involving compound components, render props, context providers, or component architecture. Includes React 19 API changes.
日本語の概要は準備中です。原文の説明を表示しています。
Medicinal chemistry filters. Apply drug-likeness rules (Lipinski, Veber), PAINS filters, structural alerts, complexity metrics, for compound prioritization and library filtering.
日本語の概要は準備中です。原文の説明を表示しています。
Personalized coding tutorials that build on your existing knowledge and use your actual codebase for examples. Creates a persistent learning trail that compounds over time using the power of AI, spaced repetition and quizes.
日本語の概要は準備中です。原文の説明を表示しています。
Query ChEMBL bioactive molecules and drug discovery data. Search compounds by structure/properties, retrieve bioactivity data (IC50, Ki), find inhibitors, perform SAR studies, for medicinal chemistry.
日本語の概要は準備中です。原文の説明を表示しています。
Query the ChEMBL database for bioactive molecules, drug targets, bioactivity data, approved drugs, and chemical structures. Use when the user asks about compounds, targets, IC50/Ki values, drug mechanisms, or structure searches.
日本語の概要は準備中です。原文の説明を表示しています。
Search PubMed for scientific literature, including published clinical trials. Fetch abstracts and full text. Link published research to biological databases (gene, protein, nucleotide, PubChem) to discover associations between papers and specific compounds or genes. Verify medical spelling, match raw citations, and cache result sets for bulk processing. Interfaces NCBI E-utilities and PMC BioC APIs.
日本語の概要は準備中です。原文の説明を表示しています。
Enumerates chemical libraries through reaction SMARTS transformations using RDKit. Generates virtual compound libraries from building blocks using defined chemical reactions with product validation. Use when creating combinatorial libraries or enumerating products from synthetic routes.
日本語の概要は準備中です。原文の説明を表示しています。
Metabolite identification from m/z and retention time. Covers database matching, MS/MS spectral matching, and confidence level assignment. Use when assigning compound identities to detected features in untargeted metabolomics.
日本語の概要は準備中です。原文の説明を表示しています。
Query BindingDB for measured drug-target binding affinities (Ki, Kd, IC50, EC50). Search by target (UniProt ID), compound (SMILES/name), or pathogen. Essential for drug discovery, lead optimization, polypharmacology analysis, and structure-activity relationship (SAR) studies.
日本語の概要は準備中です。原文の説明を表示しています。
Predicts ADMET properties using ADMETlab 3.0 API or DeepChem models. Estimates bioavailability, CYP inhibition, hERG liability, and 119 toxicity endpoints with uncertainty quantification. Filters for PAINS and other structural alerts. Use when filtering compounds for drug-likeness or prioritizing leads by predicted safety.
日本語の概要は準備中です。原文の説明を表示しています。
Manages Amazon DocumentDB end-to-end — serverless-on-8.0 cluster setup, TLS/VPC/driver config, flexible-schema and vector-search data modeling, MongoDB compatibility assessment, DMS-based migration, slow-query diagnosis, major version upgrades (4.0->5.0->8.0), Well-Architected reviews (41-check wa_review.py), cost estimation, and security hardening. Retrieve for every DocumentDB question and when the user asks to set up or migrate MongoDB to AWS — DocumentDB is AWS's MongoDB-compatible managed database. Triggers: JSON document store, document database, MongoDB on AWS, Nested fields, Lambda cannot connect, TLS handshake, VPC port 27017, IAM auth, Secrets Manager, encryption at rest, $graphLookup, flexible schema, COLLSCAN, compound index, DMS migration, CDC cutover, $vectorSearch, RAG, Global Clusters, DR replication, cost sizing, audit, health check, production-readiness.
日本語の概要は準備中です。原文の説明を表示しています。
Diagnose and fix retention problems using behavior design (B=MAP). Use when the user mentions "users sign up but dont stick around", "activation rate", "onboarding friction", "retention metrics", "why users dont complete", "churn analysis", or "aha moment". Also trigger when analyzing cohort retention curves, designing activation milestones, reducing time-to-value for new users, or investigating why users quit after their first session. Covers the Ability Chain, prompt design, and tiny behaviors that compound. For habit loops and variable rewards, see hooked-ux. For intrinsic motivation, see drive-motivation.
日本語の概要は準備中です。原文の説明を表示しています。
Finds the single constraint currently limiting a business's growth and the highest-leverage moves against it, rather than producing a list of everything that could be improved. Use this when growth has stalled or slowed, when deciding where to spend limited time or budget, when revenue rises but profit does not, when prioritizing growth initiatives, or when a business feels busy without compounding.
日本語の概要は準備中です。原文の説明を表示しています。
Filter compound libraries based on Lipinski's Rule of Five for drug-likeness.
日本語の概要は準備中です。原文の説明を表示しています。
Use when evaluating Nick Sleep-style long-term compounders: scale economies shared, customer obsession, low turnover, long runway, owner culture, and value creation through lower prices.
日本語の概要は準備中です。原文の説明を表示しています。
Use when evaluating Li Lu-style value investments: circle of competence, long-term compounding, deep research, conservative downside, China/global quality businesses, and concentrated ownership.
日本語の概要は準備中です。原文の説明を表示しています。
Query PubChem via PUG-REST API/PubChemPy (110M+ compounds). Search by name/CID/SMILES, retrieve properties, similarity/substructure searches, bioactivity, for cheminformatics.
日本語の概要は準備中です。原文の説明を表示しています。
React composition patterns that scale. Use when refactoring components with boolean prop proliferation, building flexible component libraries, or designing reusable APIs. Triggers on tasks involving compound components, render props, context providers, or component architecture. Includes React 19 API changes.
日本語の概要は準備中です。原文の説明を表示しています。
Co-creates a personal investment-research LLM Wiki (Karpathy's pattern) by interviewing the user for THEIR OWN analysis framework, not a template — a living CLAUDE.md of pure markdown + wikilinks, no RAG in place of compilation. Use to build a compounding 投研第二大脑 / 投研知识库 / 个人投研 wiki, ingest research reports / earnings calls into an existing wiki, or run post-earnings prediction→fulfillment reviews.
日本語の概要は準備中です。原文の説明を表示しています。
Set up an end-to-end test suite in any repo, following practices that make e2e a reliable per-PR gate: real flows over bypass, layered assertions, a reusable auth/session helper, video+trace evidence, and a compounding suite. Use when a repo has no e2e (or weak e2e) and you want system-level tests — "set up e2e", "add end-to-end tests", "scaffold a test gate".
日本語の概要は準備中です。原文の説明を表示しています。
Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.
日本語の概要は準備中です。原文の説明を表示しています。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
日本語の概要は準備中です。原文の説明を表示しています。
Predicts ADMET properties using ADMETlab 3.0 (119 platform features, including 77 prediction models with modeled-endpoint uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.
日本語の概要は準備中です。原文の説明を表示しています。